Company intelligence / Profile preview

CoreA Therapeutics, Inc.

Oro Valley, Arizona, United Statescoreatherapeutics.com ↗
Ownership
Private
Employees
~2
Development stage
Preclinical
01

Overview

CoreA Therapeutics specializes in developing innovative cancer immunotherapies and antibody-drug conjugates targeting solid tumors. Their proprietary platform enables the engineering of NK cells for targeted chemoimmunotherapy. No clinical results are publicly available as of May 2025.

Therapeutic areas
Oncology
Modalities
Cancer immunotherapies (including NK cell-based therapies)Antibody-drug conjugates (ADCs)
Industry
Biotech
02

Drug pipeline

1 asset

CoreA HER2-targeted NK cell chemoimmunotherapy

Preclinical

Beyond the preview

Go deeper on CoreA Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoreA Therapeutics, Inc..

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call